I agree. Especially if the primary endpoint isn’
Post# of 153886
(Total Views: 993)
Posted On: 08/10/2020 10:32:46 AM
Re: generactor #48119
I agree. Especially if the primary endpoint isn’t statistically significant. Based on what NP has said so far we should have some strong data that comes out of this trial but your average investor doesn’t understand the nuance of secondary endpoints and phase 2. (By the way, I do still hope we hit our primary I’m just spitballin’ based on what’s been said and predicted lately on the boards) Finding a balance between informing the public of results while simultaneously generating excitement and limiting any potential word tracks the shorters can abuse will require some skill. The last thing I want to see, assuming we can’t tout the primary endpoint, is something like this:
“Cytodyn announces the results of its MtoM trial with statistical significant results on three secondary endpoints. The trial, WHICH DID NOT HIT ITS PRIMARY ENDPOINT...”
In my opinion it needs to really hammer home the important stuff (just a guess on the exact results we will be able to hang our hat on) like...
“Cytodyn is pleased to announce the strong results from its MONOCLONAL ANTIBODY drug Leronlimab in a Covid-19 population of mild to moderate patients. Leronlimab reduced X, Y, and Z versus placebo. These are the first placebo-controlled trial results in the United States to show the ability to broadly treat Covid patients and reduce their risk of advancing to oxygen, ventilator, hospital stays, or of developing serious complications. With a safe side effect profile in even the most complicated patients, as well Z a second trial of severe and critical patients very close to an interim analysis, the company believes Leronlimab should become the standard of care across the broad spectrum of disease stages in Covid-19...”
Obviously I’m making some assumptions, but the point is this needs to be definitive in how great Leronlimab worked. Clear, powerful, and without confusing explanations of primary and secondary endpoints.
“Cytodyn announces the results of its MtoM trial with statistical significant results on three secondary endpoints. The trial, WHICH DID NOT HIT ITS PRIMARY ENDPOINT...”
In my opinion it needs to really hammer home the important stuff (just a guess on the exact results we will be able to hang our hat on) like...
“Cytodyn is pleased to announce the strong results from its MONOCLONAL ANTIBODY drug Leronlimab in a Covid-19 population of mild to moderate patients. Leronlimab reduced X, Y, and Z versus placebo. These are the first placebo-controlled trial results in the United States to show the ability to broadly treat Covid patients and reduce their risk of advancing to oxygen, ventilator, hospital stays, or of developing serious complications. With a safe side effect profile in even the most complicated patients, as well Z a second trial of severe and critical patients very close to an interim analysis, the company believes Leronlimab should become the standard of care across the broad spectrum of disease stages in Covid-19...”
Obviously I’m making some assumptions, but the point is this needs to be definitive in how great Leronlimab worked. Clear, powerful, and without confusing explanations of primary and secondary endpoints.
(9)
(0)